IR-Center Handelsblatt

Zur Rose Group AG

News Detail

DGAP-News News vom 30.06.2017

Zur Rose Group AG announces narrowed price range and shortens the book-building period
  • Price range narrowed to CHF 135 – CHF 140 per offered share (from previously CHF 120 – CHF 140 per offered share)
  • Book-building period to end on 4 July 2017 (one day earlier)
  • Trading on SIX Swiss Exchange expected to commence on 6 July 2017 (ticker: “ROSE”)

Due to strong demand from a broad range of investors, Zur Rose Group AG (“Group”) today announced a narrowed price range of CHF 135 – CHF 140 per share (previously CHF 120 – CHF 140), implying a total market capitalisation of approximately CHF 850 – 870 million, assuming full exercise of the Greenshoe. The Group shortened the book-building period for the Initial Public Offering (“IPO”) by one day to 4 July 2017. Following the IPO, the shares of the Group are expected to be listed and to commence trading on SIX Swiss Exchange (“SIX”) on 6 July 2017.

The book-building period will end on 4 July 2017 at 12.00 noon CEST for retail and private banking orders and 2.00 pm CEST for institutional investors, respectively. The deadline for orders under preferential allocation for existing physician customers of the Group remains unchanged (3 July 2017 at 12.00 noon CEST). The final offer price is expected to be published on 6 July 2017 before start of trading on SIX on the same day. The capital increase to create the new shares is still planned to take place on 5 July 2017.

UBS and Berenberg act as joint global coordinators and joint bookrunners for the IPO and Zürcher Kantonalbank as co-lead manager. Lilja & Co. is acting as the independent adviser to the Group and Neue Helvetische Bank contributes as selling agent.

Detailed information about the IPO is contained in the Offering Memorandum published by Zur Rose Group AG, which has been available since 22 June 2017.



Lisa Lüthi, Head of Corporate Communications

Email: [email protected], telephone: +41 52 724 08 14


Zur Rose Group

Operating under the “Zur Rose” and “DocMorris” brands, the Swiss-based Zur Rose Group is Europe’s leading pure play online pharmacy and one of Switzerland’s foremost wholesale suppliers to medical practitioners. Through its business model, it helps to ensure safe, reliable and high-quality pharmaceutical care, while also excelling in developing innovative medicines management services to increase the effectiveness of the medication process. This creation of added value, the strong focus on patients and the commitment to supply medication at low cost for the benefit of payors and patients make the Group an important strategic partner for all healthcare stakeholders.

Zur Rose Group is headquartered in Frauenfeld, from where it also serves the Swiss market. In Germany and Austria, the Group operates through subsidiaries in Heerlen (Netherlands) and Halle an der Saale (Germany). Furthermore, it holds a majority interest in BlueCare in Winterthur, the leading provider of networking systems in the Swiss healthcare market. Employing more than 800 people at its various locations, Zur Rose Group generated revenue of CHF 880 million in 2016.

Zur Rose Group AG’s shares (Swiss security no. 4261528, ISIN CH0042615283) are traded on the Berner Kantonalbank’s OTC-X, Zürcher Kantonalbank’s eKMU-X and Lienhardt & Partners Private Bank Zurich Ltd’s trading platforms. The CHF 50 million corporate bond issued in November 2012 for the purpose of financing the DocMorris acquisition is listed on the SIX Swiss Exchange (Swiss security no. 19972936, ISIN CH0199729366, ticker symbol ZRO12).



This document and the information contained herein are not for distribution in or into (directly or indirectly) the United States, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful. This document does not constitute an offer of securities for sale in or into the United States, Canada, Australia or Japan.

This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The securities of Zur Rose Group AG to which these materials relate have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will not be a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this communication will be made solely to “qualified institutional buyers” as defined in, and in reliance on, Rule 144A under the Securities Act.

This document is not an issuance or listing prospectus or a similar document in the sense of article 652a, article 752 and/or article1156 of the Swiss Code of Obligations or articles 27 et seq. of the Listing Rules of the SIX Swiss Exchange and was not reviewed by any competent authority. Any offer of securities of Zur Rose Group AG will be made solely by means of, and on the basis of, an offering memorandum that will contain detailed information about the group and its management as well as risk factors and financial statements. Any person considering the purchase of any securities of Zur Rose Group AG must inform itself independently based solely on such offering memorandum (including any supplement thereto).

This document does not constitute an "offer of securities to the public" within the meaning of Directive 2003/71/EC of the European Union, as amended (the "Prospectus Directive") of the securities referred to herein in any member state of the European Economic Area (the "EEA"). Any offers of the securities referred to in this document to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities. In any EEA Member State that has implemented the Prospectus Directive, this document is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This communication may contain statements about the future that use words such as, for example, "believe", "assume", "expect" and other similar expressions. Such statements about the future are subject to risks, uncertainties, and other factors, which can cause the true results of the company to differ significantly from that which is expressly or implicitly assumed in these statements. In view of these uncertainties, the reader should not depend on this type of statement about the future. The company gives no undertaking whatever to update such statements regarding the future, or to adapt them to future events or developments.